Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TLC

Taiwan Liposome (TLC) Stock Price, News & Analysis

Taiwan Liposome logo

About Taiwan Liposome Stock (NASDAQ:TLC)

Advanced Chart

Key Stats

Today's Range
$7.00
$7.09
50-Day Range
$6.76
$7.63
52-Week Range
$4.07
$7.70
Volume
12,421 shs
Average Volume
133,095 shs
Market Capitalization
$294.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

TLC Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

TLC Stock Analysis - Frequently Asked Questions

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) issued its quarterly earnings data on Wednesday, October, 28th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $2.28 million for the quarter, compared to analysts' expectations of $0.38 million. Taiwan Liposome had a negative net margin of 299.27% and a negative trailing twelve-month return on equity of 120.45%.

Taiwan Liposome (TLC) raised $29 million in an IPO on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor served as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taiwan Liposome investors own include Avino Silver & Gold Mines (ASM), Trevena (TRVN), Bionano Genomics (BNGO), Pfizer (PFE), Wells Fargo & Company (WFC), Aadi Bioscience (AADI) and BioLineRx (BLRX).

Company Calendar

Last Earnings
10/28/2020
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLC
CIK
1722890
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.02 million
Net Margins
-299.27%
Pretax Margin
-306.10%
Return on Equity
-120.45%
Return on Assets
-55.11%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
3.01
Quick Ratio
3.01

Sales & Book Value

Annual Sales
$3.63 million
Price / Sales
81.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.83 per share
Price / Book
8.43

Miscellaneous

Outstanding Shares
42,077,000
Free Float
N/A
Market Cap
$294.54 million
Optionable
Not Optionable
Beta
0.99
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:TLC) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners